Quick Answer
The UK MHRA confirmed in February 2026 that semaglutide (Ozempic, Wegovy) may very rarely cause NAION — a sudden optic nerve condition that can permanently damage vision. It affects fewer than 1 in 10,000 patients. Most patients should continue GLP-1 therapy but need to report sudden vision changes urgently.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
If you are taking Ozempic, Wegovy, or any semaglutide-based drug, you may have heard alarming headlines about a rare but serious eye condition called NAION — non-arteritic anterior ischemic optic neuropathy. In February 2026, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) officially updated the safety labelling for semaglutide products to include a warning about this risk. Here is an honest look at what the evidence shows, how Indian patients should think about it, and what you should watch for.
What Is NAION and Why Does It Matter
NAION stands for non-arteritic anterior ischemic optic neuropathy. In plain language, it is a sudden loss of blood flow to the optic nerve — the nerve that connects the eye to the brain and carries all visual information. When this nerve is suddenly starved of oxygen, it can cause rapid, permanent vision loss in one eye, typically noticed on waking. It is painless, sudden, and often leaves a permanent blind spot or significant reduction in vision in the affected eye.
NAION is not common in the general population — it affects roughly 2 to 10 per 100,000 people per year — but it is the second most common optic nerve disease after glaucoma. People with diabetes, high blood pressure, high cholesterol, and obstructive sleep apnea are already at higher baseline risk. These are the same conditions for which GLP-1 drugs are most frequently prescribed, which is why understanding this risk is important for Indian patients who often present with multiple overlapping metabolic conditions.
What the Studies Show
The concern about GLP-1 drugs and NAION first emerged from a study published in JAMA Ophthalmology in 2024, which found that patients prescribed semaglutide had more than 7 times the rate of NAION compared to patients on other medications. A subsequent Danish population study found a more modest but still significant signal: patients using semaglutide had approximately double the risk of developing NAION compared to matched controls on other diabetes drugs.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
In response, the European Medicines Agency launched a formal safety review in January 2025. The UK's MHRA issued its drug safety update in February 2026, concluding that semaglutide may very rarely be associated with NAION and instructing prescribers to add the condition to the warning label. The estimated frequency is classified as very rare — meaning it occurs in fewer than 1 in 10,000 patients on the drug.
It is important to note that the evidence is almost entirely observational. No randomised controlled trial has confirmed that semaglutide causes NAION — the studies have identified an association, not proven causation. People prescribed semaglutide tend to have more obesity, more diabetes, higher blood pressure, and more cardiovascular risk than the general population, all of which are independent risk factors for NAION. Separating the drug's effect from the underlying patient risk profile is genuinely difficult, and this uncertainty remains unresolved.
Why This Is Particularly Relevant for Indian Patients
Indian patients on GLP-1 drugs often carry the exact combination of risk factors that also predispose to NAION: type 2 diabetes, hypertension, high cholesterol, and obstructive sleep apnea. India has an enormous burden of diabetic eye disease — diabetic retinopathy already affects an estimated 18 million Indians — and NAION, while less widely discussed, adds to the ophthalmic risk landscape facing Indian patients with diabetes.
The practical implication is this: Indian patients starting GLP-1 therapy, particularly those with long-standing diabetes, high blood pressure, or a history of optic nerve problems, should ideally have a baseline eye examination before starting and should remain alert to any sudden changes in vision during treatment.
What Symptoms to Watch For
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
NAION typically presents as sudden, painless vision loss or a large blind spot in one eye, usually noticed on waking in the morning. There may be blurring in part of the visual field, difficulty seeing in low light, or a sudden change in colour perception in one eye. If you experience any of these symptoms while on semaglutide or tirzepatide, you should see an ophthalmologist urgently — within hours, not days. Early assessment cannot reverse NAION, but it rules out other causes of sudden vision loss that are treatable, such as retinal artery occlusion or retinal detachment.
Should You Stop Your GLP-1 Drug?
For the vast majority of patients, the answer is no. NAION is estimated to affect fewer than 1 in 10,000 GLP-1 users — a very rare event in absolute terms. In contrast, the cardiovascular, metabolic, and renal benefits of GLP-1 therapy have been demonstrated in large randomised controlled trials involving tens of thousands of patients. The benefit-to-risk ratio for most patients remains strongly positive.
The appropriate response is awareness, not alarm. Tell your GLP-1 specialist about any history of eye problems, particularly optic nerve disease, high intraocular pressure, or previous episodes of sudden vision change. Have a baseline eye check before starting if you have long-standing diabetes or hypertension. Report any sudden vision changes promptly. These are sensible precautions, not reasons to avoid a therapy whose benefits — for weight, blood sugar, cardiovascular protection, and kidney health — are among the most robustly proven in modern medicine.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. UK MHRA — Drug Safety Update: Semaglutide and NAION, February 2026 — https://assets.publishing.service.gov.uk/media/69847cb7468d351e1406b4d2/DSU_-_Semaglutide_and_NAION_-_5_Feb_2026.pdf 2. Medical News Today — Ozempic and vision loss: GLP-1 drugs may double risk of eye disease — https://www.medicalnewstoday.com/articles/more-research-links-glp-1-drugs-semaglutide-tirzepatide-potentially-blinding-eye-diseases-vision-loss 3. American Optometric Association — GLP-1 Receptor Agonists and vision risk — https://www.aoa.org/news/clinical-eye-care/public-health/glp-1-receptor-agonists-and-vision-risk
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.